Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.37 |
| ▸ | DRD3 | P35462 | 8/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692088 | 1.00 | DRD2 (0.37) | DRD2DRD3ADRA2ARXRARXRB | |
| SCHEMBL22709595 | 0.86 | DRD2 (0.37) | DRD2DRD3ADRA2A | |
| SCHEMBL29423749 | 0.86 | DRD2 (0.37) | DRD2DRD3ADRA2A | |
| SCHEMBL22709130 | 0.86 | DRD2 (0.37) | DRD2DRD3ADRA2A | |
| SCHEMBL22692006 | 0.82 | SIGMAR1 (0.40) | ADRA2A | |
| Ethylene SCHEMBL11704541 | 0.70 | ADRA2A (0.43) | DRD2DRD3ADRA2ASRD5A1 | |
| SCHEMBL22692100 | 0.70 | SIGMAR1 (0.40) | ADRA2A | |
| SCHEMBL22692123 | 0.68 | NOTUM (0.34) | — | |
| SCHEMBL29423684 | 0.68 | HTR1A (0.35) | — | |
| SCHEMBL6505565 | 0.67 | GRM8 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-21 | — | — | US | disclosed |
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972978-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236940-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | DRD2 4855/4885DRD3 4845/4885ADRA2A 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.